News

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular...

Aurisco, a pharmaceutical company and contract development and manufacturing organization (CDMO) in China, is cooperating with global life sciences company Cytiva, to build its first Oligo FlexFactory platform for commercial production. The Oligo FlexFactory platform is the first of the...

Sartorius has extended a strategic collaboration agreement with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. The companies will provide solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based...

Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation ("Alcami"), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison...

Duality Biologics, a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced a license agreement with Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough...

Agilent Technologies Inc. has acquired Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer. The acquisition complements Agilent’s SureSelect portfolio and further augments...

Capsida Biotherapeutics Inc. has entered a multi-year strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Co., to develop genetic medicines for serious diseases. Prevail will leverage Capsida's novel adeno-associated virus (AAV) engineering platform to...